Beyond Air, Inc. (XAIR) Stock Price & Analysis

Beyond Air, Inc. (XAIR) fell 1.67% to USD 3.53 as of September 8, 2026 at 09:03 UTC, according to Nexqual real-time market data.

XAIR last closed at USD 3.53; the session ranged USD 3.5–3.64 on volume of 48,543 shares. Market capitalization is —, with a 52-week range of USD 3.5–60 (NCM). Source: Nexqual, September 8, 2026 at 09:03 UTC.

Key Statistics (as of September 8, 2026 at 09:03 UTC)

Technical Analysis (XAIR)

Nexqual's technical model rates XAIR "SELL" based on 1 bullish and 5 bearish signals across 128 daily candles, as of September 8, 2026 at 09:03 UTC.

From Beyond Air, Inc.'s Latest SEC 10-K Filing (filed 2026-06-26)

Key Strengths & Strategy (as disclosed to the SEC)

• Beyond Air has 84.75% ownership in NeuroNOS.       Our approved commercial product and development pipeline of product candidates is shown in the tables below:             LungFit ® PH is the first FDA-approved and CE Mark system using our patented plasma pulse technology to generate on-demand NO from ambient air and, regardless of dose or flow, deliver it to a ventilator circuit.
• We believe the approval and subsequent launch of the LungFit ® PH II will equip our commercial organization to become the market leader in the U.S. in the near-term.   LungFit ® PRO for the treatment of viral lung infections in hospitalized patients   Viral Community-Acquired Pneumonia (including COVID-19)   Viral pneumonia in adults is most commonly caused by rhinovirus, respiratory syncytial virus ("RSV") and influenza virus.
• The funding is being used to accelerate ongoing preclinical work, including IND-enabling studies as well as for general corporate purposes.   In April 2025, the FDA granted Orphan Drug Designation ("ODD") to NeuroNos' investigational therapy, BA-102, for the treatment of Phelan-McDermid Syndrome ("PMS"), a syndrome associated with ASD.
• On December 13, 2022, we announced the publication of preclinical data in the peer-reviewed journal Cancer Cell International (CCI), which showed that our proprietary tumor ablation technology utilizing UNO induced a potent innate and adaptive immune response that prevented metastases and resulted in a statistically significant survival benefit.   In April 2023, Beyond Cancer presented additional preclinical data for UNO therapy in solid tumors during the AACR 2023 annual meeting.

Partnerships

• To date, no such gas-based therapy has been approved for commercialization by the FDA or other regulatory agencies.   NeuroNos has entered into an agreement with Yissum Research Development Company of the Hebrew University of Jerusalem, LTD. to acquire the commercial rights for neuronal nitric oxide synthase (nNOS) inhibitors being developed for the treatment of autism spectrum disorder ("ASD") and other neurological conditions.
• On June 15, 2023, the Company announced that it has entered into an agreement with Yissum Research Development Company of the Hebrew University of Jerusalem, LTD. (the "University") to acquire the commercial rights for nNOS inhibitors being developed for the treatment of ASD and other neurological conditions.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 09:03 UTC. This page is informational and not investment advice.